Cell Harvester Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Displacement Collector, Therapy Collector), By Application (Cell Proliferation Assays, Mixed Lymphocyte Culture (MLC) Assays, Receptor-Binding Assays, Single-Stranded Template DNA Harvesting, Others), By Region and Competition, 2020-2030F

Market Overview

Global Cell Harvester Market was valued at USD 3.21 Billion in 2024 and is expected to reach USD 4.63 Billion by 2030 with a CAGR of 6.48%. Cell harvesters are essential devices used to isolate, collect, and prepare cells from various biological sources for clinical, research, and therapeutic applications. These systems are widely adopted in regenerative medicine, cancer research, and cell-based diagnostics, fueling market expansion across both developed and emerging economies.

One of the primary drivers of the global cell harvester market is the expanding field of regenerative medicine, which relies heavily on the efficient extraction and preparation of viable cells. The increasing incidence of cancer and other life-threatening conditions has led to a surge in stem cell therapies, immunotherapies, and personalized medicine, all of which require advanced cell harvesting technologies. Despite the positive outlook, the market faces challenges such as high capital investment, stringent regulatory requirements, and the complexity of large-scale cell processing.

Key Market Drivers

Growth in Healthcare Industry

The expansion of the global healthcare industry stands as a significant catalyst for the growth of the cell harvester market. The global healthcare industry generates annual revenues exceeding USD 4 trillion. Among its most lucrative and expansive segments are pharmaceuticals and biotechnology, contributing nearly USD 850 billion, followed by medical technology and diagnostics, which account for over USD 400 billion. As healthcare systems across both developed and emerging economies continue to evolve, there is a marked increase in investments toward advanced medical technologies, including cell harvesting equipment. The rising demand for precision medicine, regenerative therapies, and stem cell-based treatments is creating a favorable environment for the adoption of cell harvesting solutions in clinical and research settings.

Moreover, the growing burden of chronic diseases such as cancer, cardiovascular conditions, and autoimmune disorders has intensified the focus on cell-based therapies. In 2021, noncommunicable diseases (NCDs) were responsible for approximately 43 million deaths, representing 75% of all non-pandemic-related fatalities worldwide. Cardiovascular diseases constituted the leading cause of NCD-related mortality, accounting for an estimated 19 million deaths. This was followed by cancer, with 10 million deaths, chronic respiratory diseases at 4 million, and diabetes including diabetes-induced kidney disease contributing to over 2 million deaths. These therapeutic approaches often require the collection and processing of specific cell types, thereby boosting the need for efficient and reliable cell harvesting devices. Hospitals, biopharmaceutical companies, and academic research institutions are increasingly incorporating these technologies to facilitate improved treatment outcomes and accelerate translational research.

Surge in Technological Advancements

The global cell harvester market is witnessing robust growth, largely driven by rapid technological advancements that have significantly enhanced the efficiency, precision, and scalability of cell harvesting processes. Automated cell harvesters mark a substantial advancement in cell harvesting by delivering efficiencies that are challenging to attain through manual techniques. Leveraging sophisticated robotics and integrated software algorithms, these systems optimize and accelerate the harvesting process, enabling high-throughput cell collection with enhanced precision and consistency. Innovations in biomedical engineering, automation, and biotechnology are reshaping the landscape, allowing for more sophisticated applications across research, clinical, and therapeutic domains.

One of the primary advancements fueling this growth is the integration of automated and closed-system technologies in cell harvesting platforms. These innovations minimize the risk of contamination, reduce manual intervention, and streamline workflow factors that are particularly critical in clinical settings and Good Manufacturing Practice (GMP) environments. The development of next-generation cell harvesters equipped with real-time monitoring and data analytics capabilities is further enhancing process control and reproducibility, aligning with the growing demand for standardized and high-throughput operations in biopharmaceutical manufacturing.

Download Free Sample Report

Key Market Challenges

High Cost of Devices and Procedures

One of the most significant challenges impeding the growth of the global cell harvester market is the high cost associated with both the devices and the procedures they support. Cell harvesting technologies, especially those designed for clinical-grade applications, often involve advanced features such as automation, real-time monitoring, and sterile closed systems. While these features enhance precision and reduce contamination risks, they also substantially increase the capital and operational costs of the equipment.

For many healthcare institutions, research laboratories, and small-to-mid-sized biopharmaceutical companies, the initial investment required for cell harvesters can be prohibitively expensive. In addition to the equipment itself, associated costs such as installation, maintenance, training, and consumables add to the financial burden. These expenses are particularly restrictive in developing economies, where healthcare budgets are limited and access to cutting-edge biotechnology is constrained.

Key Market Trends

Advancements in Regenerative & Personalized Medicine

The rapid advancements in regenerative and personalized medicine have emerged as a prominent trend shaping the growth trajectory of the global cell harvester market. Stem cell transplantation has gained prominence as a promising approach in regenerative medicine, offering significant potential for tissue repair in cases of degenerative diseases and physical injuries. This field encompasses the identification and isolation of diverse stem cell types, including embryonic, induced pluripotent, and adult stem cells sourced from various origins. These innovative medical approaches rely heavily on the collection and manipulation of patient-specific cells, driving the need for advanced and precise cell harvesting technologies. As personalized therapies become increasingly mainstream, the demand for reliable tools that can isolate and preserve viable cells with high specificity and efficiency continues to rise.

Regenerative medicine, which includes stem cell therapies, tissue engineering, and cellular therapies, requires the extraction of high-quality cells to develop treatments that can repair or replace damaged tissues and organs. This has led to a surge in the adoption of automated and closed-system cell harvesters, which ensure consistency, sterility, and scalability. Simultaneously, the growing interest in autologous therapies where a patient's own cells are used for treatment has further intensified the need for individualized and minimally invasive cell harvesting solutions.

Segmental Insights

Type Insights

Based on Type, Displacement Collector have emerged as the fastest growing segment in the Global Cell Harvester Market in 2024. This is driven by its operational efficiency, enhanced cell recovery rates, and adaptability across diverse biomedical applications. This growth is underpinned by the increasing demand for high-yield, contamination-free cell harvesting systems that support both clinical and research workflows. Displacement collectors are particularly valued for their ability to facilitate gentle and efficient separation of cells from culture media without compromising cell integrity. This feature is crucial in applications such as stem cell therapy, regenerative medicine, and monoclonal antibody production, where maintaining the viability and functionality of harvested cells is essential.

Application Insights

Based on Application, Cell Proliferation Assays have emerged as the fastest growing segment in the Global Cell Harvester Market during the forecast period. This is due to their expanding role in a wide range of biomedical and pharmaceutical research applications. These assays are critical for evaluating cell growth, viability, and cytotoxicity factors that are fundamental to drug discovery, cancer research, regenerative medicine, and stem cell studies. As the demand for personalized and precision medicine grows, so too does the need for accurate and high-throughput proliferation analysis, thereby accelerating the adoption of advanced cell harvesting systems designed to support such assays.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Cell Harvester Market in 2024. The region benefits from a highly developed healthcare infrastructure, which facilitates early adoption and integration of advanced medical technologies, including automated and closed-system cell harvesting devices. Leading biopharmaceutical and biotechnology companies headquartered in the United States and Canada have made significant investments in cell therapy, regenerative medicine, and biologics manufacturing driving consistent demand for high-efficiency harvesting systems across clinical and commercial applications.

Recent Development

• In October 2024, contract development and manufacturing organization (CDMO) AmplifyBio secured access to Xcellbio’s Avatar Foundry system, facilitating small-scale cell therapy workflows. This strategic collaboration supports the transition from small-scale processes to larger-scale, automated cell therapy manufacturing. It also enables the development of cell-based potency assays with enhanced predictive capabilities for in vivo efficacy and supports the generation of IND-enabling datasets for human papillomavirus (HPV) TCR candidates. The Avatar platform comprising the Avatar Odyssey, Avatar Ai, and Avatar Foundry instruments is specifically engineered to support cell therapy production and potency assessment. All three instruments incorporate hyperbaric incubation technology, allowing for the simulation of diverse in vivo microenvironments, including the tumor microenvironment.
• In May 2025, Novartis Contract Manufacturing revealed its plans to enhance its biologics production capabilities by introducing a state-of-the-art cell culture system at its drug substance manufacturing site in Kundl, Austria. This strategic move is part of the company’s broader effort to expand and modernize its infrastructure to meet the growing global demand for high-quality biologic therapies. The new protein manufacturing line is progressing as scheduled and is anticipated to be GMP-compliant by the third quarter of 2025. In addition to this development, the Kundl site currently offers a comprehensive range of services, including microbial drug substance manufacturing, the preparation and storage of master and working cell banks, and the production of plasmid DNA and RNA, reinforcing its position as a key hub in Novartis’s global manufacturing network.
• In August 2024, the Advanced Research Projects Agency for Health (ARPA-H) introduced the Democratized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic (ET). This initiative is designed to advance innovative quality assurance technologies and expedite the generation of critical evidence required to support reimbursement pathways for rare disease therapies. Academic medical centers (AMCs) have been instrumental in developing transformative treatments for both adults and children with rare conditions, including those involving autologous cell therapy (ACT), a process that involves collecting a patient’s own cells or tissues and engineering them into personalized therapies. ARPA-H intends to make the technologies and methodologies developed under the DECIDE-ET program widely accessible to industry stakeholders.
• In May 2024, AVITA Medical, Inc., a commercial-stage regenerative medicine company specializing in first-in-class wound care and skin restoration technologies, announced that the U.S. Food and Drug Administration (FDA) had approved its premarket approval (PMA) supplement for the RECELL GO System. This next-generation autologous cell harvesting device leverages a patient’s own skin to support the treatment of thermal burns and full-thickness skin defects. RECELL GO incorporates advanced features designed to simplify the preparation of Spray-On Skin Cells, significantly reduce training requirements for clinical staff, enhance procedural workflow in the operating room, and precisely manage RECELL Enzyme incubation to maximize cell yield and viability.

Key Market Players

• Human Med AG
• ADS Biotec Inc.
• PerkinElmer Inc.
• Cytiva
• TERUMO BCT, INC.
• Esco Micro Pte. Ltd.
• Gasser Apparatebau und Laborzubehör
• Sartorius AG
• Cox Scientific Ltd.
• Pall Corporation

Report Scope

In this report, the Global Cell Harvester Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cell Harvester Market, By Type:

o   Displacement Collector

o   Therapy Collector

• Cell Harvester Market, By Application:

o   Cell Proliferation Assays

o   Mixed Lymphocyte Culture (MLC) Assays

o   Receptor-Binding Assays

o   Single-Stranded Template DNA Harvesting

o   Others

• Cell Harvester Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Harvester Market.

Available Customizations:

Global Cell Harvester Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Cell Harvester Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]